HeartWare (NASDAQ:HTWR) Receives Another Recommendation From Wall Street


How Sun Trust Rbsn Humphrey Currently Rates HeartWare (NASDAQ:HTWR)

In an analyst note sent to clients and investors today, Sun Trust Rbsn Humphrey analysts began issuing HeartWare (NASDAQ:HTWR) coverage with “Buy” rating.

From a total of 14 analysts covering Heartware International Inc (NASDAQ:HTWR) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 8 a ”Hold”. This means that 43% of the ratings are positive. The highest target price is $102 while the lowest target price is $44. The mean of all analyst targets is $63.21 with a 60.65% above today’s ($49.3) stock price. Heartware International Inc was the topic of 24 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. SunTrust initiated shares on December 8 with “Buy” rating. Oppenheimer maintained shares with “Buy” rating and $100 target share price in a report from a September 3. BTIG Research upgraded HTWR stock in a recent report from October 26 to “Buy” rating. BTIG Research maintained the rating on August 9. BTIG Research has a “Buy” rating and a $105 price target on shares. Finally, William Blair maintained the stock with “Market Perform” rating in a report issued on a September 6.

The stock increased 2.94% or $1.41 during the last trading session, striking $49.3. Approximately shares of stock traded hands. HeartWare International Inc (NASDAQ:HTWR) has declined 35.64% since May 6, 2015 and is downtrending. It has underperformed by 34.84% the S&P500.

Heartware International, Inc. is a medical device company. The company has a market cap of $829.22 million. The Firm develops and makes miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. It currently has negative earnings. The HeartWare Ventricular Assist System , which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure.

According to Zacks Investment Research, “HeartWare International, Inc. along with its subsidiaries is a medical device company focused on developing and commercializing small implantable pumps for the treatment of chronic and end-stage heart failure. Its principle product, the HeartWare Ventricular Assist System, includes a left ventricular assist device, related accessories and surgical tools and is designed to provide circulatory support for patients with advanced heart failure. The company is also developing the Miniaturized Ventricular Assist Device focused on minimally invasive implantation techniques. HeartWare is also developing a portfolio of further miniaturized devices, implantable by progressively less invasive surgery. The Company’s corporate headquarters are in Framingham, Massachusetts and its operating and manufacturing activities are based in Miami Lakes, Florida.” Get a free copy of the Zacks research report on HeartWare International Inc (HTWR).